Narinder Janghra

812 citations
17 papers · 531 · h-index 8

Impact in

  • Genetics top 5%
    • Neurogenetic and Muscular Disorders Research
  • Oncology top 10%
    • CAR-T cell therapy research
    • HER2/EGFR in Cancer Research

Papers in

  • Oncology 11
    • CAR-T cell therapy research 7
    • HER2/EGFR in Cancer Research 5
  • Molecular Biology 9
    • Cancer therapeutics and mechanisms 3
    • Muscle Physiology and Disorders 2
Co-authors
Jennifer E. Morgan (4 shared papers)Francesco Muntoni (3 shared papers)Patrick H. van Berkel (11 shared papers)Haiyan Zhou (2 shared papers)Francesca Zammarchi (11 shared papers)John A. Hartley (8 shared papers)Peter Tyrer (6 shared papers)David G. Williams (5 shared papers)
Journals
Cancer Research (7 papers)Molecular Cancer Therapeutics (2 papers)Blood (2 papers)JAMA Neurology (1 paper)Human Molecular Genetics (1 paper)
Partner nations
United KingdomSwitzerlandThailand

In The Last Decade

Narinder Janghra

16 papers receiving 510 citations

Peers

Narinder Janghra
Comparison fields: 5 of 42
  • Genetics 165
  • Oncology 213
  • Radiology, Nuclear Medicine and Imaging 111
  • Pathology and Forensic Medicine 66
  • Molecular Biology 267
Replace Daniel Xia with:
Daniel Xia United States
Hiromi Kanno Japan
Alfred Yung United States
Thuy Trinh Germany
H. I. Robins United States
Steven Park United States
Bertrand Actor Germany
Ondřej Kalita Czechia
Raffaella Albano Italy
Patricia Rakopoulos Canada
Narinder Janghra relative to Daniel Xia United States Daniel Xia's profile →
Citations per field
00.5×2×3.2×
Daniel Xia · 1×
Citations per year

Countries citing papers authored by Narinder Janghra

Since Specialization
Citations

This map shows the geographic impact of Narinder Janghra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narinder Janghra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narinder Janghra more than expected).

Fields of papers citing papers by Narinder Janghra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narinder Janghra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narinder Janghra. The network helps show where Narinder Janghra may publish in the future.

Co-authors

The 25 scholars most cited alongside Narinder Janghra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Narinder Janghra Line = papers co-authored together Narinder Janghra links everyone, so they are left out of the graph.

All Works

17 of 17 papers shown
#Work
1
ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
Blood ·Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E. Britten, Carin E.G. Havenith, Simon Chivers, François D’Hooge, David G. Williams, Arnaud Tiberghien, Philip W. Howard, John A. Hartley, Patrick H. van Berkel
2018132
2
A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice
Human Gene Therapy ·Haiyan Zhou, Narinder Janghra, Chalermchai Mitrpant, Rachel L. Dickinson, Karen Anthony, Loren Price, Ian C. Eperon, (unknown), Jennifer E. Morgan, Francesco Muntoni
2013104
3
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Molecular Cancer Therapeutics ·Michael Flynn, Francesca Zammarchi, Peter Tyrer, Ayse U. Akarca, Narinder Janghra, Charles E. Britten, Carin E.G. Havenith, Jean-Noel Levy, Arnaud Tiberghien, Luke A. Masterson, Conor S. Barry, François D’Hooge, Teresa Marafioti, Paul W.H.I. Parren, David G. Williams, Philip W. Howard, Patrick H. van Berkel, John A. Hartley
201698
4
Biochemical Characterization of Patients With In-Frame or Out-of-FrameDMDDeletions Pertinent to Exon 44 or 45 Skipping
JAMA Neurology ·Karen Anthony, Virginia Arechavala‐Gomeza, Valeria Ricotti, Silvia Torelli, Lucy Feng, Narinder Janghra, Giorgio Tasca, Michela Guglieri, Rita Barresi, Annarita Armaroli, Alessandra Ferlini, K. Bushby, Volker Straub, Enzo Ricci, Caroline A. Sewry, Jennifer E. Morgan, Francesco Muntoni
201363
5
Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response
Human Molecular Genetics ·Haiyan Zhou, Jinhong Meng, Elena Marrosu, Narinder Janghra, Jennifer E. Morgan, Francesco Muntoni
201543
6
Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies
PLoS ONE ·Narinder Janghra, Jennifer E. Morgan, Caroline A. Sewry, Francis X. Wilson, Kay E. Davies, Francesco Muntoni, Jonathon M. Tinsley
201634
7
Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers
UCL Discovery (University College London) ·Francesca Zammarchi, Karin Havenith, Simon Chivers, Paul W. Hogg, François Bertelli, Peter Tyrer, Narinder Janghra, Halla W. Reinert, John A. Hartley, Patrick H. van Berkel
202229
8
ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Molecular Cancer Therapeutics ·Francesca Zammarchi, Karin Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, François Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A. Hartley, Patrick H. van Berkel
20248
9
Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Blood ·Michael Flynn, Patrick H. van Berkel, Francesca Zammarchi, Peter Tyrer, Ayse U. Akarca, Narinder Janghra, Vishvesh Shende, (unknown), Teresa Marafioti, David G. Williams, Philip W. Howard, John A. Hartley
20156
10
Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors
Cancer Research ·Francesca Zammarchi, Halla W. Reinert, Narinder Janghra, Simon Corbett, Maria Mellinas‐Gomez, Sajidah Chowdhury, Neha Arora, Peter Tyrer, François Bertelli, David G. Williams, Philip W. Howard, John A. Hartley, Patrick H. van Berkel
20174
11
Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers
Cancer Research ·Francesca Zammarchi, Karin Havenith, Lolke de Haan, Ian Kirby, Narinder Janghra, Veronica Gil, Pedro Alves, Kristina Zaitseva, Meghann Kerr, Ben Leatherdale, Afroze Patel, Marie Thoelke, Shiran Huang, John A. Hartley, Patrick H. van Berkel
20232
12
Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6
Cancer Research ·Nicola Tsang, Nicolas Veillard, Elizabeth Horsley, Karin Havenith, Narinder Janghra, Kristina Zaitseva, Cecile Oblette, Ian Kirby, Paul W. Hogg, Francesca Zammarchi, Lolke de Haan, Patrick H. van Berkel
20242
13
Abnormalities of the cadherin–catenin complex in chemically-induced colo-rectal carcinogenesis
Proceedings of The Nutrition Society ·Elizabeth R. Tucker, Andrea Buda, Narinder Janghra, Jennifer H.E. Baker, James E. Coad, Morganden Moorghan, M. E. Havler, Peter W. Dettmar, Massimo Pignatelli
20032
14
Abstract 1580: HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers
Cancer Research ·Danilo Cucchi, Elizabeth Horsley, Alina Chrzastek, Ben Leatherdale, Simone Sims, Nicole Bledowski, Banusha Rajeenthira, Narinder Janghra, Lara Montolio, Abigail Kimpalu, Christopher M. Gallagher, Charlie Britten, Lolke de Haan, Paul W. Hogg, Chris Pickford, Patrick H. van Berkel
20251
15
Abstract 5085: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b
Cancer Research ·Elizabeth Horsley, Asma Jabeen, Nicolas Veillard, Karin Havenith, Narinder Janghra, Pedro Alves, Cecile Oblette, Ian Kirby, Paul W. Hogg, Francesca Zammarchi, Lolke de Haan, Patrick van Berkel
20241
16
Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies
Cancer Research ·Francesca Zammarchi, Simon Corbett, Karin Havenith, Narinder Janghra, Konstantinos Kiakos, Teresa Marafioti, David G. Williams, Simon Chivers, Phil W. Howard, John A. Hartley, Patrick H. van Berkel
20171
17
Abstract 1604: Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2
Cancer Research ·Francesca Zammarchi, Karin Havenith, Ben Leatherdale, Britanny Roberts, Lara Montolio, Afroze Patel, Narinder Janghra, Pedro Alves, Kristina Zaitseva, Cecile Oblette, Ian Kirby, Lolke de Haan, Patrick H. van Berkel
20231

About Narinder Janghra

Narinder Janghra is a scholar working on Oncology, Molecular Biology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 17 papers that have together received 531 indexed citations. Recurring topics across this work include CAR-T cell therapy research (7 papers), HER2/EGFR in Cancer Research (5 papers), Cancer therapeutics and mechanisms (3 papers), Neurogenetic and Muscular Disorders Research (2 papers), Muscle Physiology and Disorders (2 papers), Synthesis and pharmacology of benzodiazepine derivatives (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Toxin Mechanisms and Immunotoxins (2 papers). The work is most often cited by research in Genetics (165 citations), Oncology (213 citations), Radiology, Nuclear Medicine and Imaging (111 citations), Pathology and Forensic Medicine (66 citations) and Molecular Biology (267 citations). Narinder Janghra has collaborated with scholars based in United Kingdom, Switzerland and Thailand. Frequent co-authors include Jennifer E. Morgan, Francesco Muntoni, Patrick H. van Berkel, Haiyan Zhou, Francesca Zammarchi, John A. Hartley, Peter Tyrer, David G. Williams, Karen Anthony and Arnaud Tiberghien. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Blood, JAMA Neurology and Human Molecular Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel XiaBreakdown of academic impact, for papers by Hiromi KannoBreakdown of academic impact, for papers by Alfred YungBreakdown of academic impact, for papers by Thuy TrinhBreakdown of academic impact, for papers by H. I. RobinsBreakdown of academic impact, for papers by Steven ParkBreakdown of academic impact, for papers by Bertrand ActorBreakdown of academic impact, for papers by Ondřej KalitaBreakdown of academic impact, for papers by Raffaella AlbanoBreakdown of academic impact, for papers by Patricia Rakopoulos